On April 17, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company, held a special meeting of stockholders to vote on several key proposals. The meeting saw a quorum with proxies representing approximately 39% of the outstanding shares. The primary agenda was the approval of a Charter Amendment for a Reverse Stock Split, which was adopted with 2,058,182 votes in favor and 899,831 against. The approved amendment allows the board of directors to effect a reverse stock split at a ratio between 1-for-2 and 1-for-50, at their discretion, without further stockholder approval. Additionally, a proposal to adjourn the meeting to solicit more proxies was approved, but rendered moot as the Reverse Stock Split received sufficient votes. The board has set the reverse stock split ratio at 1-for-10, to take effect at 4:01 p.m. Eastern Time on April 25, 2024. ZyVersa Therapeutics' common stock will trade on a post-split basis on The Nasdaq Capital Market starting April 26, 2024, under a new CUSIP number 98987D 300.

On April 17, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company, held a special meeting of stockholders to vote on several key proposals. The meeting saw a quorum with proxies representing approximately 39% of the outstanding shares. The primary agenda was the approval of a Charter Amendment for a Reverse Stock Split, which was adopted with 2,058,182 votes in favor and 899,831 against. The approved amendment allows the board of directors to effect a reverse stock split at a ratio between 1-for-2 and 1-for-50, at their discretion, without further stockholder approval. Additionally, a proposal to adjourn the meeting to solicit more proxies was approved, but rendered moot as the Reverse Stock Split received sufficient votes. The board has set the reverse stock split ratio at 1-for-10, to take effect at 4:01 p.m. Eastern Time on April 25, 2024. ZyVersa Therapeutics' common stock will trade on a post-split basis on The Nasdaq Capital Market starting April 26, 2024, under a new CUSIP number 98987D 300.